It is not clear whether a B clade-based vaccine will be efficacious in areas of the world where non-B clade strains are endemic or whether non-B clade-based vaccines could be more effective immunogens for these regions. The issue is further complicated by the presence of multiple non-B clades in many
Ninety-five percent of human immunodeficiency virus (HIV) infections worldwide occur in the developing world, with Africa bearing the highest burden. Most of the 10 major HIV-1 subtypes have been found in sub-Saharan Africa, but the most prevalent are non-B clades [1] . Although cross-clade cytotoxic T lymphocyte (CTL) responses have been demonstrated in several studies [2] [3] [4] [5] [6] [7] , the immune responses elicited in the natural infection by non-B clade strains of HIV-1 in Africa have not been well characterized. Furthermore, HLA allele frequencies vary greatly among African populations and may influence not only epitope presentation but also the degree and strength of cross-recognition.
It is not clear whether a B clade-based vaccine will be efficacious in areas of the world where non-B clade strains are endemic or whether non-B clade-based vaccines could be more effective immunogens for these regions. The issue is further complicated by the presence of multiple non-B clades in many affected populations. The first HIV-1 vaccine trial in Africa is currently taking place in Uganda, with a clade B-based vaccine. The level of cross-clade immune responses that can be elicited by a clade B immunogen will be assessed in a region where clade A and D strains predominate.
In this study, we present data relevant to the vaccine trial currently under way in Uganda. We evaluated the cellular immune responses elicited in naturally infected Ugandans and compared recognition of endemic clade A or D strains in Uganda with that of clade B strains. CTL responses to the homologous clade (same clade) virus were examined, as well as cross-reactivity to the heterologous coendemic virus and clade B virus.
Subjects and Methods
Subjects. Seventeen HIV-1-infected (clade A or D) Ugandan volunteers were studied (figure 1). The volunteers were selected from the TB Prevention Cohort from the Mulago Hospital in Kampala, Uganda. Individuals included seroprevalent HIV-infected volunteers (designated SP) and recent seroconverters (documented HIV-1 seroconversion within 6 months [designated RC]), with plasma HIV-1 RNA ranging from 5100 to 690,000 copies/mL. The CD4 cell counts for these individuals ranged from 150 to 1104 cells/ mm 3 . Subtyping was performed by polymerase chain reaction sequencing of the C2-V3 region, using methods described elsewhere [2] , and the nucleotide sequences were submitted to GenBank (accession numbers AF289616-AF289632).
Vaccinia viruses. Clade B recombinant vaccinia viruses used were vAbT 141 (Gag), vAbT 299 (Env), vCF 21 (RT), and vT23 (Nef) [2] . Non-B clade recombinant vaccinia vectors were obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Dis- Phylogenetic analysis was performed by the neighbor-joining method, and reliability was estimated from 100 bootstrap resamplings. Representative sequences of various HIV-1 subtypes, A-J, were included in the analysis. Alignment was subject to 1000 bootstrap resamplings; the number of resamplings is indicated at major branch points. Horizontal distance corresponds to genetic relatedness. Analysis and alignment were performed with Clustal software version 1.6 (European Molecular Biology Laboratory, Heidelberg, Germany), with minor manual adjustment when necessary. ELISPOT assay. The ELISPOT assay was performed on cryopreserved peripheral blood mononuclear cells (PBMC). Ninetysix-well nitrocellulose plates (Millititer; Millipore, Bedford, MA) were coated overnight at 4ЊC with 0.5 mg/mL of monoclonal antibody (MAb) 1-D1K (Mabtech, Stockholm). The plates were then washed 6 times with PBS, and PBMC were added at 50,000 cells per well and 25,000 cells per well in duplicate wells, respectively. Autologous B lymphoblastic cell lines (B-LCLs) infected overnight with recombinant vaccinia viruses expressing designated HIV-1 proteins from different clades were washed twice and added to the same wells at a final effector:target (E:T) ratio of 5:1 to 1:1 (the New York City Board of Health strain was used as the control vector). In assays with peptides, direct loading of PBMC with synthetic peptides at a final concentration of 100 mg/mL was used, with media alone as control. Biotinylated MAb anti-interferon (IFN)-g MAbs (Mabtech) then were added at 0.5 mg/mL for 100 min, followed by streptavidin-alkaline phosphatase (Mabtech) for 1 h at room temperature. The plates were washed 3 times with PBS, and 5-bromo-4-chloro-3-indolyl phosphate and nitro blue (Sigma, St. Louis) were added to develop the reaction. Tap water was added to stop the reaction after 15 min. Individual cytokineproducing cells were detected as dark spots that were visualized and quantitated as spot-forming cells per well. CTL precursor frequency (CTLp) was calculated from the number of spots subtracted from the control wells and was averaged from the 4 wells. The final CTLp was reported as the average frequency per 10 6 cells. Responses were considered positive if the frequency of the spot-forming cells was at least twice that of control. Background spot-forming cells were, on average, !15 per well.
Chromium release assay. A standard 4-h chromium release assay was performed, as described elsewhere [2] , with B-LCLs infected with specific recombinant vaccinia viruses (at an MOI of 3-5) or pulsed with synthetic peptides and labeled with 51 Cr (New England Nuclear, Boston). The highest MOIs that yielded maximal expression, as evidenced by lysis level on multiple target cells, were used. Target cells were washed twice and incubated with effector cells at 37ЊC in 5% CO 2 , and supernatants were harvested after 4 h. All assays were performed in duplicate, and the percentage of lysis was determined from the following formula:
experi-100 ϫ [( mental release maximum -release Ϫ spontaneous )/( release Ϫ spon taneous release)] [8] . HIV-specific CTL activity was defined as 10% above background or control and presented as lysis level substracted from control. Spontaneous release was !30% of maximal release for all assays. All bulk assays were repeated and confirmed with у2 separate assays, and cross-clade lysis was considered higher if 110%.
Effector cells for cytolytic assays were derived from cryopreserved PBMC that had been expanded into CD8 ϩ cell populations with the CD3:CD4-bispecific MAb (CD3/4b) [9] and had been stimulated with autologous Epstein-Barr virus-transformed B cells infected with recombinant vaccinia virus expressing HIV-1 gene products [2] . CTL clones were generated by using methods described elsewhere [8] . In brief, PBMC were plated in 96-well plates at limiting dilution (10-100 cells per well) and were cultured with irradiated allogeneic feeder PBMC at 50,000 cells per well in a final volume per well of 200 mL of R10 medium (RPMI 1640, 10% fetal calf serum, and 10 mM HEPES buffer [M-2-hydroxyethylpiperazine-N-ethanesulfonic acid; all from Sigma]) with antibiotics (2 mM Lglutamine and 50 U of penicillin-streptomycin/mL). The anti-CD3 MAb, 12F6 [10] , was added at 100 mg/mL, and the cells were maintained in culture in the presence of recombinant interleukin (rIL)-2; Hoffman-LaRoche, Nutley, NJ).
Epitope mapping for Gag-and Env-specific responses was performed with autologous or partially HLA-matched target cells sensitized with 25-mer overlapping peptides spanning the targeted viral RC 264  ----RC 475  53  ---RC 656  16  ---RC 691  -22  --RC 970  ----SP 503  ----SP 508  ----SP 510  ----SP 511  13  -35  -SP 513  12  ---SP 520  ----SP 522  28  -60  13  SP 524  ----SP 528  21  42  --SP 533  11  ---SP 539  - protein. Subsequent fine mapping was achieved with a series of overlapping shorter peptides spanning the identified 25-mer peptide. Serial peptide dilutions further defined the optimal epitope by determining the minimal peptide concentration required for lysis.
For the peptide titration assay, serial 10-fold dilutions from a peptide concentration of 100 mg/mL to 10 pg/mL were performed on 96-well plates. Peptides were added directly to the well and were incubated with washed chromium-labeled target cells (final concentration, 10 4 cells per well) for 60 min, at a volume of 100 mL. Effector clones (E:T ratio 5:1) were added, to a final volume of 200 mL.
CTL precursor frequency analysis. PBMC were seeded at 250-16,000 cells per well in 24 replicate wells of a 96-well plate in the presence of media containing 12F6 at 0.1 mg/mL. Gamma-irradiated ( ) allogeneic PBMC were added as feeder cells, and 4 2.5 ϫ 10 rIL-2 (50 U/mL) was added the next day [8] . Precursor HIV-specific cytolytic activity was assessed by autologous B-LCLs that had been infected with recombinant vaccinia viruses expressing HIV-1 proteins from various clades as target cells. Wells for which lysis was 110% above that of the 24 control wells were scored as positive, and the percentage of nonresponding wells was calculated for each dilution. Cell frequency was estimated by the maximum-likelihood method [11] .
Results
To compare cellular immune responses to various clades, CD8-expanded cells from clade A-and clade D-infected individuals were stimulated by B-LCLs infected with clade A and clade D recombinant vaccinia viruses, respectively [2] . CTL activity was then tested with autologous B-LCL target cells expressing clade A, B, or D proteins, in a standard chromium release assay. We found that the spectrum of CTL activity elicited from non-B clade viruses was broad and included Gag, Env, Pol, and Nef reactivity (figure 2). Five of 7 people were infected with clade A viruses and demonstrated CTL activity specific for Gag ( ELISPOT assays have been used to detect and quantitate HIV-1-specific CD8 ϩ T lymphocytes in infected people [12, 13] . These measure the IFN-g that is secreted after contact with HIV-specific targets in vitro [14] and correlate well with lytic assays. We used this method to quantitate CTL and compare responses among the different viral subtypes. Discrepancy with the limiting dilution assay data might reflect the different stim- Systematic epitope mapping was performed on several individuals, resulting in identification of HLA class I-restricted epitopes (figures 4 and 5). The optimal Gag epitope for clone SP511 (clade A) was conserved for clades B and D (figure 4). In contrast, the SP528 (clade A) Env CTL epitope recognized heterologous clade B sequence and not clade D, which suggests that cross-recognition of heterologous clades is not readily predicted on the basis of the presence of local circulating strains ( figure 5 ). In addition, 6 people infected with clade A with HLA haplotypes A2 ( ), A3 ( ), and B7 ( ) were n p 3 n p 1 n p 2 screened for activity against known CTL Gag peptide epitopes (LAI aa 18-26, 20-26, 77-85, 74-86, and 167-175) [15] . Despite conservation in clade A viral sequences, no CTL activity was detected by the ELISPOT method (data not shown).
Discussion
The development of an effective HIV vaccine that is broadly applicable to populations exposed to multiple HIV-1 clades is problematic. First, the antigenic diversity among different isolates and clades and the varying genetic makeup among target populations might impede the development of an effective immunogen [16, 17] . Second, the correlates of protective immunity in HIV-1 infection remain undefined. Although many factors may contribute to protection [18] , the current consensus suggests that an effective HIV vaccine will need to induce virusspecific CTLs.
Significant CTL cross-reactivity, with evidence of either epitope conservation or cross-clade recognition, has been demonstrated [2-4, 7, 19] . This has provided initial support for initiating vaccine trials that use clade B immunogens in Uganda, where clade B viruses are not prevalent but where the need for a vaccine is most urgent. The results of the present study of HIV-1-infected Ugandans indicate that the most robust HIV-specific cytotoxic T cells are directed to the homologous clade. In addition, CTL responses in this cohort of infected Ugandans cross-recognize the nonendemic clade B strain just as well as, if not more strongly than, they recognize the coendemic heterologous clade. Analysis of these results suggests that the use of a clade A immunogen for Uganda might not result in full cross-reactive CTL responses in the Ugandan population, because it may not be better than a clade B-based vaccine in conferring protection against clade D infection. In addition, the CTL response in this cohort is distinct from that described in white populations [15, 20] , which may reflect the properties of the endemic HIV viral isolates and genetic makeup of the Ugandan population.
The need for an effective AIDS vaccine is urgent, as the epidemic continues to expand. Our results indicate that a single clade vaccine candidate might not elicit broadly reactive responses in regions in which multiple endemic clades are present. The region-specific cellular immune responses underscore the potential difficulty of designing a broadly effective vaccine that is epitope based. Because the precise role of HIV-specific CTL is still emerging, detailed analyses of this response in various regions may provide new insights into HIV pathogenesis. Further studies of the immune responses in natural infection and vaccinated populations, particularly in non-B clade regions of the world, will be critical to the rational development of a broadly immunogenic HIV vaccine.
